FTY720

A board to discuss future MS therapies in early stage (Phase I or II) trials.

FTY720

Postby bromley » Thu Sep 14, 2006 2:00 am

Some news on FTY720 - further data to be presented at the end of the month.

Ian

Phase II Data Showing Clinical Benefits of Novel Once-Daily Oral Multiple Sclerosis Therapy FTY720 (Fingolimod) Published in New England Journal of Medicine

* One-year data show significant reductions in inflammatory disease activity and clinical relapse activity with daily oral FTY720 were maintained for up to one year
* Phase III program investigating FTY720 now being implemented in the U.S.

Clinical trial results published in the New England Journal of Medicine showed that FTY720 (fingolimod), a novel once-daily oral compound, demonstrated significant benefits in the treatment of various relapsing forms of multiple sclerosis (MS). Based on the positive Phase II study results, Novartis has launched a Phase III pivotal study program to further evaluate FTY720's benefits in patients with the relapsing-remitting form of multiple sclerosis (RRMS).

The Phase II data show that during the initial six months of treatment, oral FTY720 taken once-daily reduced the rate of inflammatory disease activity, measured by magnetic resonance imaging or MRI, by up to 80% compared to placebo and also reduced the rate of clinical relapses by more than 50%. In patients who continued FTY720 treatment during the subsequent six-month extension, low levels of disease activity were maintained as measured by both MRI and relapses, and both these measures decreased in patients who switched from placebo to FTY720.

"These results demonstrate that once-daily oral FTY720 provides a significant and rapid improvement in MRI measures of inflammation, as well as in relapse-related clinical endpoints in patients with relapsing multiple sclerosis," said Chief Investigator Professor Ludwig Kappos, MD, of the Department of Neurology at the University Hospital in Basel, Switzerland. "If the magnitude of benefits shown in this Phase II study are confirmed in the larger-scale Phase III study program, oral FTY720 could represent a major improvement in the way MS will be treated in the future."

The recently launched global Phase III pivotal study program called FREEDOMS (FTY720 Research Evaluating Effects of Daily Oral therapy in Multiple Sclerosis) will include over 100 study centers and over 2,000 patients worldwide with RRMS. The randomised, double-blind, placebo-controlled study will evaluate the efficacy and safety of two orally-administered doses of FTY720 (1.25 mg and 0.5 mg) as compared to placebo in reducing the frequency of relapses in patients treated for up to 24 months. Other objectives include evaluation of efficacy on disability progression, Magnetic Resonance Imaging (MRI) lesion parameters as well as safety and tolerability of FTY720 (1.25 mg and 0.5 mg) compared to placebo.

Phase II study results

The Phase II study described in the New England Journal of Medicine was conducted at 32 centers in 11 countries (in Europe and Canada) to evaluate the effect of FTY720 on disease activity as measured by MRI and relapses as well as its safety and tolerability.

In the initial placebo-controlled phase, 281 patients were randomised equally to receive FTY720 1.25 mg, FTY720 5 mg or placebo once-daily for six months. Of the 255 patients who completed this part of the study, 98% volunteered to continue in the extension phase. Patients in the placebo group were then re-randomised to receive either FTY720 1.25 mg or 5 mg blinded for an additional six months, while those already on the study drug continued with their original treatment.

This study showed that once-daily oral FTY720 provides significant improvement in MRI measures of inflammation and in relapse-related clinical endpoints in patients with relapsing MS. Inflammatory disease activity as measured by the total cumulative number of gadolinium (Gd)-enhancing MRI lesions was significantly reduced by up to 80% (p<0.001 in FTY720 1.25 mg, p<0.006 in FTY720 5 mg) compared to placebo over six months of treatment. At six months, the proportion of patients free of Gd-enhancing lesions was also greater in both FTY720 groups compared to placebo (p<0.001 for both groups) with a separation between the curves becoming evident from two months onwards.

In both the groups taking FTY720 (1.25 mg or 5 mg), patients who had experienced a reduction in their annualised relapse rate of more than 50% compared to placebo during the first six months of the study maintained this low relapse rate during the subsequent six-month extension study.

In patients who switched from placebo to either dosage of FTY720 after six months, the annualised relapse rate was reduced by at least 70% during the six-month extension study compared to the period on placebo.

Relapse rates were reduced by 55% in the FTY720 1.25 mg group (p=0.009) and by 53% in the FTY720 5 mg group (p=0.014) compared to placebo. Time to first confirmed relapse was also significantly prolonged in both FTY720 groups compared to placebo (p=0.007 in FTY720 1.25 mg, p=0.01 in FTY720 5 mg). More than 80% of patients who received FTY720 for up to 12 months were free from lesions showing active inflammation on MRI at month 12, irrespective of their treatment dose.

In the six-month placebo-controlled phase of the study, the most frequent adverse events reported for FTY720 were dose-dependent upper respiratory tract infections (mainly nasopharyngitis), and dyspnea plus diarrhea, and nausea. FTY720 treatment was associated with initial dose-dependent decreases in heart rate and expiratory flow. Clinically asymptomatic increases in alanine aminotransferase (liver enzyme) and increase in blood pressure were also observed. There were no unexpected safety findings during the six-month extension phase as compared to the six-month placebo-controlled phase. The ongoing Phase III study program includes comprehensive safety monitoring which will provide further assessment of the safety profile.

An analysis of two-year phase II data with FTY720 will be presented at the European Congress for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Madrid later this month.

About FTY720

FTY720 is the first in a new class of disease-modifying treatments called sphingosine 1-phosphate receptor (S1P-R) modulators and has a novel mode of action different from all currently marketed MS therapies. FTY720 has been developed by Novartis and licensed from Mitsubishi Pharma Corporation.

Source: Novartis Pharmaceuticals Corporation
User avatar
bromley
Family Elder
 
Posts: 1887
Joined: Fri Sep 10, 2004 3:00 pm

Advertisement

Postby carolew » Thu Sep 14, 2006 8:42 am

I am still waiting for a phone call to start participating in this trial.
I am slowly getting worse and do not want to.
Waiting for these trials to start is heart-wrenching.
I should post in the 'daily life 'section about my feelings....
User avatar
carolew
Family Elder
 
Posts: 553
Joined: Fri Nov 05, 2004 4:00 pm
Location: Ottawa, Ont. Canada

Postby flipflopper » Thu Sep 14, 2006 9:28 am

Hi Carole,

Recruitment for the clinical trial should begin soon. You can call Novartis at 1 866 788-3930 to ask questions you might have about the fingolimod study. I called a few weeks ago because I feel the exact same way you do and I was impatient to hear when it might begin.
User avatar
flipflopper
Family Elder
 
Posts: 183
Joined: Wed Nov 09, 2005 4:00 pm

Postby flipflopper » Thu Sep 14, 2006 1:28 pm

Ohh...and I just got an e-mail from the MNI telling me that the study will begin soon. I’m sure they will start recruiting soon in Ottawa too.
User avatar
flipflopper
Family Elder
 
Posts: 183
Joined: Wed Nov 09, 2005 4:00 pm

Postby carolew » Fri Sep 15, 2006 8:35 pm

Hey Flip, thanks, I will call them. My neuro was still working on some special arrangements to make the study very safe and I see her next week. I hope all is clear and that it will start soon.
I am getting worse, slowly but surely. I want to start something now, now I mean. So, soon hopefully, you or I will be able to post that it has finally started. Keep in touch please, you encourage me.
User avatar
carolew
Family Elder
 
Posts: 553
Joined: Fri Nov 05, 2004 4:00 pm
Location: Ottawa, Ont. Canada

Postby carolew » Thu Nov 02, 2006 7:04 pm

Finally, I had my first visit for this phase lll study on fingolimod. Finally. I have been waiting so long. I hope that Flipflopper has started too.
They sure do a thorough evaluation. Check your concentration and your coordination. I did things I never did before like putting pegs in wholes and maths to show them that my brain still works.
Anyway, I am so glad to start this product. My first dose il in early Dec'06 if all goes well. Finally. Hope I am not in the placebo group cause I have stropped my dear Lipitor and I miss it... Will keep you posted,
Take care, Carolew
User avatar
carolew
Family Elder
 
Posts: 553
Joined: Fri Nov 05, 2004 4:00 pm
Location: Ottawa, Ont. Canada

Postby CureOrBust » Fri Nov 03, 2006 4:19 am

carolew wrote:Hope I am not in the placebo group cause I have stropped my dear Lipitor and I miss it...

Did they tell you to stop the lipitor? or was it on your own accord?
User avatar
CureOrBust
Family Elder
 
Posts: 2914
Joined: Wed Jul 27, 2005 3:00 pm
Location: Sydney, Australia

Postby scoobyjude » Fri Nov 03, 2006 4:24 pm

Good Luck Carolew!! We'll be pulling for you :D
User avatar
scoobyjude
Family Elder
 
Posts: 516
Joined: Sat Feb 18, 2006 4:00 pm
Location: suburb of Chicago, IL USA

Postby carolew » Sat Nov 04, 2006 6:57 am

wow, thanks!
User avatar
carolew
Family Elder
 
Posts: 553
Joined: Fri Nov 05, 2004 4:00 pm
Location: Ottawa, Ont. Canada

Postby carolew » Sat Nov 04, 2006 7:01 am

Cureorbust: No. I stopped it because the FTY720 also can make your liver enzymes increase, like the Lipitor, I didn't want to risk it. It is actually not on the list of drugs that are prohibited. :? I just don't want t be refused because my enzymes are too high. I have missed out on other studies for different reasons and I don't want to mess this one. Take care. Carole
User avatar
carolew
Family Elder
 
Posts: 553
Joined: Fri Nov 05, 2004 4:00 pm
Location: Ottawa, Ont. Canada

Postby flipflopper » Sat Nov 04, 2006 10:52 am

carolew wrote:Finally, I had my first visit for this phase lll study on fingolimod. Finally. I have been waiting so long. I hope that Flipflopper has started too.


I have been doing some thinking about the Fingolimod clinical trial. I finally decided that I felt more comfortable trying out for Tovaxin (3 hour drive from home). I feel bad enough as it is (fatigue and dizziness…I am also in the middle of a relapse). And, I already know that I don’t tolerate interferons well at all and I don't want to risk being on it for one year! Hence, Tovaxin seemed more appealing to me than the Avonex vs Fingolimod trial. And, since I am progressing now, I didn’t feel comfortable with the Fingolimod vs placebo arm of the clinical trial (I don’t want to be on nothing for 2 years). I still think it is too early to have really high hopes for Tovaxin. But, I will still be trying out for it as my number one choice.

Now, Fingolimod is my plan B. If I am not accepted into the Tovaxin trial, and if they are still recruiting for Fingolimod, I will join right away.


And, if they are no longer recruiting for Fingolimod, I guess I will decide what to do then.




But I wish you the Best of luck with Fingolimod Carole!
User avatar
flipflopper
Family Elder
 
Posts: 183
Joined: Wed Nov 09, 2005 4:00 pm

Postby carolew » Sat Nov 04, 2006 11:10 am

I do understand Flip, 2 years on nothing is not appealing. My study is the one where I have a chance to be on placebo (one in three), no interferons.
I am having a hell of a time off my Lipitor. If I end up on the placebo, I may just restart it....I am actually already back on 20mg per day. Could not picture myself working without it.
I really hope the Tovaxin trial works for you Flip. Our days are a constant struggle and you need a user friendly trial that will make our life easier.
Take care and keeps us posted.
I guess I should have a plan B too.... Will have to think about that one.
Carole
User avatar
carolew
Family Elder
 
Posts: 553
Joined: Fri Nov 05, 2004 4:00 pm
Location: Ottawa, Ont. Canada

Postby carolew » Thu Dec 07, 2006 7:27 pm

Ok, OK, I got my first dose by mouth today!!!

They had to take my vitals signs every hour for 6 hrs so I got to just sit there for 6 hrs and read without interruptions. Nice...

All went well, therefore I don't know if I am getting the drug or the placebo.
One probably doesn't get side effects from just one dose.

I heard that the person before me yesterday, also had no problems. She is # 1 patient and I am #2. Odds are one in 3 for the placebo.

Maybe it really is a drug that is easy to tolerate but, boy, I would love to have one little tiny side effect so I could tell if I am on it or not.

So, I continue as usual and will keep you posted.
Take care, Carolew
User avatar
carolew
Family Elder
 
Posts: 553
Joined: Fri Nov 05, 2004 4:00 pm
Location: Ottawa, Ont. Canada

Postby Lyon » Thu Dec 07, 2006 8:05 pm

00
Last edited by Lyon on Mon Jun 20, 2011 3:34 pm, edited 1 time in total.
Lyon
Family Elder
 
Posts: 6063
Joined: Wed May 03, 2006 3:00 pm

Postby flipflopper » Thu Dec 07, 2006 9:27 pm

I might end up joining you after all.

I got a call saying that I could try a second time for the Tovaxin trial. I’m sure I’ll be negative again for MRTC's but I will try another time. If I’m not accepted and if they are still recruiting for Fingolimod (I was told by the nurse in charge of the trial in Montreal that they will probably still be recruiting by then) I will probably join.

Once again, good luck Carole!
User avatar
flipflopper
Family Elder
 
Posts: 183
Joined: Wed Nov 09, 2005 4:00 pm

Next

Return to Drug Pipeline

 


  • Related topics
    Replies
    Views
    Last post
  • FTY720
    by bromley » Tue Jul 19, 2005 11:03 am
    1 Replies
    1487 Views
    Last post by carolew View the latest post
    Sun Aug 07, 2005 3:44 am
  • FTY720
    by bromley » Mon Jul 25, 2005 5:55 am
    1 Replies
    1509 Views
    Last post by carolew View the latest post
    Sun Aug 07, 2005 3:48 am
  • FTY720
    by bromley » Sat Oct 01, 2005 1:54 am
    1 Replies
    1589 Views
    Last post by carolew View the latest post
    Sat Oct 01, 2005 12:18 pm
  • FTY720
    by bromley » Thu Mar 16, 2006 10:29 am
    4 Replies
    1896 Views
    Last post by billf View the latest post
    Thu Mar 23, 2006 11:32 am
  • FTY720
    by bromley » Mon Apr 24, 2006 3:17 am
    1 Replies
    1569 Views
    Last post by lorienhome View the latest post
    Sun Jun 04, 2006 6:30 am

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service